Literature DB >> 15146167

Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium.

Sylvia Aust1, Peter Obrist, Walter Jaeger, Martin Klimpfinger, Gerhard Tucek, Friedrich Wrba, Edward Penner, Theresia Thalhammer.   

Abstract

Epithelium of the gallbladder and biliary tract is exposed to high concentrations of potentially harmful exogenous and endogenous compounds excreted into primary bile. As the ATP-dependent efflux pump ABCG2 can prevent cellular accumulation of anticancer drugs, estrogen sulfate, xenobiotics, porphyrins, and sterols, its expression in the biliary tract might mediate protection by hindering their penetration. We therefore investigated the expression and subcellular distribution of ABCG2 in normal and malignant human gallbladder. After demonstrating ABCG2 expression in gallbladder epithelium by RT-PCR and Western blotting, we analyzed the subcellular localization of ABCG2 by indirect immunofluorescence in gallbladder adenocarcinoma specimens, and compared it to that in cholelithiasis, and normal gallbladder samples (n = 54). In control, cholelithiasis, and well-differentiated tumor samples (grade 1, T1-3), ABCG2 is present at the luminal membrane of epithelial cells, which was proven by colocalization of apical-bound TRITC-labeled lectin (wheat germ agglutinin). In poorly differentiated gallbladder adenocarcinomas, intracellular ABCG2, in addition to luminal ABCG2 immunoreactivity, was found in 13/21 carcinoma samples (grade 2 and 3, T2-4, P < 0.01). In 3/11 of grade 3 tumors, ABCG2 was present in the cytoplasmatic compartment only (P < 0.01). In proliferating bile ducts of cholangiocarcinomas, ABCG2 showed an analogous staining pattern with presence in cytosolic compartments. However, the apical marker enzyme neutral endopeptidase remained on the membrane in all samples. To study whether phosphatidylinositol 3-kinase (PI3K) signaling might be necessary for ABCG2 membrane insertion, we treated freshly isolated human gallbladder epithelial cells with the PI3K inhibitor wortmannin. As assessed by indirect immunofluorescence, this maneuver redistributes ABCG2 to intracellular compartments. In conclusion, our data suggest a protective role for ABCG2 in well-differentiated gallbladder epithelial cells. Cytoplasmatic accumulation of ABCG2 in poorly differentiated carcinomas might coincide with malfunctioning of PI3K-signaling pathways during tumor progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146167     DOI: 10.1038/labinvest.3700127

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  13 in total

1.  Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.

Authors:  Kenneth K W To; Brian Tomlinson
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 2.  Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport.

Authors:  Kousei Ito; Hiroshi Suzuki; Toshiharu Horie; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

3.  Role of the breast cancer resistance protein (ABCG2) in drug transport.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2005-05-11       Impact factor: 4.009

4.  Human ABCG2: structure, function, and its role in multidrug resistance.

Authors:  Wei Mo; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2011-03-30

5.  Pancreatic stellate/myofibroblast cells express G-protein-coupled melatonin receptor 1.

Authors:  Sylvia Aust; Walter Jäger; Harald Kirschner; Martin Klimpfinger; Theresia Thalhammer
Journal:  Wien Med Wochenschr       Date:  2008

Review 6.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

Review 7.  ABCG2: a perspective.

Authors:  Robert W Robey; Kenneth K K To; Orsolya Polgar; Marius Dohse; Patricia Fetsch; Michael Dean; Susan E Bates
Journal:  Adv Drug Deliv Rev       Date:  2008-12-16       Impact factor: 15.470

Review 8.  Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Authors:  Curtis D Klaassen; Lauren M Aleksunes
Journal:  Pharmacol Rev       Date:  2010-01-26       Impact factor: 25.468

9.  Repression of genes involved in melanocyte differentiation in uveal melanoma.

Authors:  Marjorie-Allison Bergeron; Sophie Champagne; Manon Gaudreault; Alexandre Deschambeault; Solange Landreville
Journal:  Mol Vis       Date:  2012-07-04       Impact factor: 2.367

10.  AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.

Authors:  Kun Liu; Yan-Chi Li; Yu Chen; Xiao-Bao Shi; Zi-Hao Xing; Zheng-Jie He; Sheng-Te Wang; Wei-Jing Liu; Peng-Wei Zhang; Ze-Zhong Yu; Xue-Mei Mo; Mei-Wan Chen; Zhe-Sheng Chen; Zhi Shi
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.